Detalhe da pesquisa
1.
AngioJet Pharmacomechanical Thrombectomy and Catheter Directed Thrombolysis vs. Catheter Directed Thrombolysis Alone for the Treatment of Iliofemoral Deep Vein Thrombosis: A Single Centre Retrospective Cohort Study.
Eur J Vasc Endovasc Surg
; 60(4): 578-585, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32665201
2.
Two Year Outcome After Chronic Iliac Vein Occlusion Recanalisation Using the Vici Venous Stent®.
Eur J Vasc Endovasc Surg
; 56(5): 710-718, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30139572
3.
D-Dimer elevation and adverse outcomes.
J Thromb Thrombolysis
; 39(1): 55-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25006010
4.
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
Thromb Haemost
; 121(5): 616-624, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33202447
5.
Effect of thrombophilia on clinical outcomes of chronic post-thrombotic patients after iliofemoral stenting with nitinol venous stents.
J Vasc Surg Venous Lymphat Disord
; 9(4): 888-894, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186751
6.
Idraparinux versus standard therapy for venous thromboembolic disease.
N Engl J Med
; 357(11): 1094-104, 2007 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-17855670
7.
Extended prophylaxis of venous thromboembolism with idraparinux.
N Engl J Med
; 357(11): 1105-12, 2007 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-17855671
8.
Machine learning to predict venous thrombosis in acutely ill medical patients.
Res Pract Thromb Haemost
; 4(2): 230-237, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32110753
9.
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
Health Technol Assess
; 19(83): vii-xxiii, 1-93, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26490434
10.
Thromboembolic disease in surgery for malignancy-rationale for prolonged thromboprophylaxis.
Semin Thromb Hemost
; 28(6): 569-76, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12536350